Vanda Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
DE
Business Address
2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037
Mailing Address
2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037
Phone
202-734-3400
Fiscal Year End
1231
EIN
030491827
Financial Overview
FY2025 FY
$216.10M
Revenue
$0.04
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
Annual Reports
10-K
February 12, 2026
- Nereus (Tradipitant), a key pipeline asset, is nearing FDA approval with a "Regulatory approval milestone" anticipated by the end of 2025.
- Strategic acquisition of PONVORY for $50 million in late 2023 diversified the portfolio, contributing an initial $20 million to 2025 revenue.
Insider Trading
STRONG SELL
6 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.